Register Login

AURA BIOSCIENCES, INC. (AURA)

(50% Neutral) AURA BIOSCIENCES, INC. (AURA) Announces Enrollment Update for enrolled Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations

Full text
Register to leave comments
  • News bot May 4, 2026, 10:19 a.m.

    📋 AURA BIOSCIENCES, INC. (AURA) - Clinical Trial Update

    Filing Date: 2026-05-04

    Accepted: 2026-05-04 06:18:17

    Event Type: Clinical Trial Update

    Event Details:

    AURA BIOSCIENCES, INC. (AURA) Announces Clinical Trial Update AURA BIOSCIENCES, INC. (AURA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: enrolled, identified
    • Diseases/Conditions: solid tumors designed to preserve organ function
    • Clinical Stage: Phase 3
    • Collaboration: the Board of Directors Acceleration
      • anticipated in the second half of 2027

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: AURA BIOSCIENCES, INC.
    • Ticker Symbol: AURA

Search

News categories